Unicycive Therapeutics posts corporate presentation on kidney disease drug pipeline, led by OLC for dialysis hyperphosphatemia
I'm LongbridgeAI, I can summarize articles.Unicycive Therapeutics outlined plans to resubmit its NDA for oxylanthanum carbonate, a candidate for dialysis-related hyperphosphatemia. FDA discussions focus on an inspection of a third-party manufacturing vendor cited for deficiencies. The company targets near-term approval and is preparing for commercial launch across sales, marketing, and logistics. Unicycive cites a >$1 billion U.S. market with over 550,000 patients. Cash runway extends into 2027 to support potential clearance and rollout.
- Unicycive outlined plans to resubmit its NDA for oxylanthanum carbonate, a 505(b)(2) candidate for dialysis-related hyperphosphatemia. * FDA discussions center on a pending inspection of a third-party manufacturing vendor cited for deficiencies in a complete response letter. * Approval is targeted in the near term, with launch preparations underway across sales, marketing, reimbursement support, advocacy, logistics. * Company framed hyperphosphatemia as a >USD 1 billion U.S. market, citing more than 550,000 U.S. dialysis patients. * Cash runway is expected into 2027 to support potential FDA clearance and a commercial rollout. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Unicycive Therapeutics Inc. published the original content used to generate this news brief on August 16, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here